Antiplatelet therapy in acute coronary syndromes |
| |
Authors: | Colin M Barker Matthew J Price |
| |
Institution: | (1) Division of Cardiovascular Diseases, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA |
| |
Abstract: | Acute coronary syndromes (ACS), characterized by unstable angina or a non-ST-segment elevation myocardial infarction, are
caused by rupture of an atherosclerotic plaque, leading to platelet activation and aggregation, thrombus formation, and microembolization.
Antiplatelet therapy is a cornerstone of therapy. Combined with aspirin, clopidogrel provides significant benefit for patients
across the ACS spectrum. However, clopidogrel has limitations given its slow onset and the inconsistent level of inhibition
that it achieves. Newer thienopyridine and non-thienopyridine P2Y12 receptor agonists offer the advantages of a rapid onset
of action and greater and more consistent platelet inhibition. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|